Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Danicopan PK in hepatic impairment
NCT03555539Phase 1Completed
- Sponsor
- Alexion Pharmaceuticals
- Start
- May 2018
- Primary completion
- Sep 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of danicopan in paroxysmal nocturnal hemoglobinuria (PNH) (2 arms), sponsored by Alexion Pharmaceuticals. Primary endpoints: Area Under The Plasma Concentration Versus Time Curve From Time 0 Extrapolated To Infinity, Area Under The Plasma Concentration Versus Time Curve From Time 0 To The Last Measurable Concentration and 2 more. Started May 2018; status: completed.
02
Drugs
danicopan
03
Conditions
paroxysmal nocturnal hemoglobinuria (PNH)
Beyond the preview
Go deeper on NCT03555539.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03555539.